Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Net Income towards Common Stockholders: 2022-2025

Historic Net Income towards Common Stockholders for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$44.2 million.

  • Entrada Therapeutics' Net Income towards Common Stockholders fell 215.75% to -$44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 288.29%. This contributed to the annual value of $65.6 million for FY2024, which is 1087.80% up from last year.
  • Entrada Therapeutics' Net Income towards Common Stockholders amounted to -$44.2 million in Q3 2025, which was down 2.45% from -$43.1 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Net Income towards Common Stockholders peaked at $55.0 million during Q2 2024, and registered a low of -$44.2 million during Q3 2025.
  • Its 3-year average for Net Income towards Common Stockholders is -$4.2 million, with a median of -$9.5 million in 2023.
  • In the last 5 years, Entrada Therapeutics' Net Income towards Common Stockholders soared by 449.49% in 2024 and then tumbled by 215.75% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$24.6 million in 2022, then spiked by 61.43% to -$9.5 million in 2023, then soared by 111.63% to $1.1 million in 2024, then plummeted by 215.75% to -$44.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$44.2 million for Q3 2025, versus -$43.1 million for Q2 2025 and -$17.3 million for Q1 2025.